Hatch, A., Madden, S., Kohn, M
Recombinant enzyme replacement therapy (ERT) using agalsidase- and agalsidase- clears cellular deposits of Gb3 and improves disease burden, respectively 11,12
18 raises the possibility that this group failed to observe beneficial effects with peptides lacking 9092 because their peptides were not capped on either terminus
They appear to be specialized to their area
The Promising Findings GHK-Cu has the most robust human evidence, particularly for topical skincare applications BPC-157 shows impressive results in animal studies for wound healing, collagen production, and tissue repair Peptides generally have favorable safety profiles in the studies that exist The mechanisms make biological sense: peptides do play real roles in healing The Limitations Most studies on BPC-157 and TB-500 are animal-based, not human There are no standardized dosing protocols for most injectable peptides Long-term safety data in humans is limited Many peptides are not FDA-approved for cosmetic or surgical recovery purposes Quality control varies widely between compounding pharmacies Important: Many injectable peptides are classified as research compounds and are not approved for human use outside of clinical trials
